Denise de Lima Bezerra Agnes, Matias de Sousa Iasmin, Silva de Souza Ana Priscilla, Miranda de Carvalho Ana Lúcia, Trussardi Fayh Ana Paula
Postgraduate Program in Health Sciences, Health Sciences Center, Federal University of Rio Grande do Norte, Natal, RN, Brazil.
Postgraduate Program in Health Sciences, Health Sciences Center, Federal University of Rio Grande do Norte, Natal, RN, Brazil; Liga Norteriograndense Contra o Câncer, Natal, RN, Brazil.
Clin Nutr ESPEN. 2023 Feb;53:268-273. doi: 10.1016/j.clnesp.2022.12.013. Epub 2022 Dec 16.
This study aims to evaluate the effect of early nutritional intervention on adverse clinical events in women with breast cancer undergoing neoadjuvant chemotherapy.
This is a randomized clinical trial performed at the beginning of neoadjuvant chemotherapy for women with breast cancer treated at an oncology referral center (Brazil) and followed until the end of radiotherapy period, at least. Registered under ClinicalTrials.gov Identifier no. RBR-3SHHXS.
Participants were allocated to a control group - CG (nutritional guidance on healthy eating practices) or an intervention group - IC (nutritional guidance and individualized food plan). Chemotherapy toxicity (primary endpoint) was considered a precocious adverse clinical event and it was evaluated by self-reported gastrointestinal symptoms observed at any time during the first three cycles of treatment. Post-surgical complications, radiotherapy toxicity, and weight change were considered long-term adverse events.
34 women (19 in the IG and 15 in the CG) were evaluated. The early nutritional intervention was associated with low gastrointestinal chemotoxicity (nausea, vomiting, and constipation, p < 0.001, p < 0.048, and p < 0.024, respectively). However, there were no statically significant differences between both groups in the presence of long-term adverse events (radiotherapy toxicity-88.2% vs 76.9%, weight loss-21.1% vs 26.7% for IC and CG respectively, p > 0.05 for both).
The early nutritional intervention was associated with a low frequency of precocious events, but not with long-term adverse events in women with breast cancer during treatment.
本研究旨在评估早期营养干预对接受新辅助化疗的乳腺癌女性不良临床事件的影响。
这是一项随机临床试验,在一家肿瘤转诊中心(巴西)对接受新辅助化疗的乳腺癌女性患者开始治疗时进行,至少随访至放疗期结束。在ClinicalTrials.gov上注册,标识符为RBR-3SHHXS。
参与者被分配到对照组(CG,关于健康饮食做法的营养指导)或干预组(IC,营养指导和个性化饮食计划)。化疗毒性(主要终点)被视为一种早熟的不良临床事件,并通过在治疗的前三个周期中任何时间观察到的自我报告的胃肠道症状进行评估。术后并发症、放疗毒性和体重变化被视为长期不良事件。
对34名女性(IG组19名,CG组15名)进行了评估。早期营养干预与低胃肠道化学毒性相关(恶心、呕吐和便秘,p<0.001、p<0.048和p<0.024)。然而,两组在长期不良事件方面没有统计学上的显著差异(放疗毒性——IG组88.2%,CG组76.9%;体重减轻——IG组和CG组分别为21.1%和26.7%,两者p>0.05)。
早期营养干预与早熟事件的低发生率相关,但与乳腺癌女性治疗期间的长期不良事件无关。